Eur J Pharmacol . No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial

[tetano]

Eur J Pharmacol


. 2021 Feb 16;173947.
doi: 10.1016/j.ejphar.2021.173947. Online ahead of print.
No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial


Hamidreza Jamaati ¹ , Seyed MohammadReza Hashemian ¹ , Behrooz Farzanegan ² , Majid Malekmohammad ² , Payam Tabarsi ³ , Majid Marjani ³ , Afshin Moniri ⁴ , Zahra Abtahian ¹ , Sara Haseli ¹ , Esmaeil Mortaz ⁵ , Alireza Dastan ⁶ , Abdolreza Mohamadnia ¹ , Abdolbaset Vahedi ¹ , Fatemeh Monjazebi ⁷ , Fatemeh Yassari ¹ , Lida Fadaeizadeh ⁸ , Ali Saffaei ⁹ , Farzaneh Dastan ¹⁰



Affiliations

• PMID: 33607104
• PMCID: PMC7885705
• DOI: 10.1016/j.ejphar.2021.173947

Abstract

The aim of this study was to evaluate the clinical effects of dexamethasone administration in patients with mild to moderate acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19). The study included 50 patients who were randomly assigned to the dexamethasone group or control group. Dexamethasone was administered at a dose of 20 mg/day from day 1-5 and then at 10 mg/day from day 6-10. The need for invasive mechanical ventilation, death rate, duration of clinical improvement, length of hospital stay, and radiological changes in the computed tomography scan were assessed. The results revealed that 92% and 96% of patients in the dexamethasone and control groups, respectively, required noninvasive ventilation (P = 0.500). Among them, 52% and 44% of patients in the dexamethasone and control groups, respectively, required invasive mechanical ventilation (P = 0.389). At the end of the study, 64% of patients in the dexamethasone group and 60% of patients in the control group died (P = 0.500); the remaining patients were discharged from the hospital during the 28-day follow-up period. The median length of hospital stay was 11 days in the dexamethasone group and 6 days in the control group (P = 0.036) and the median length of hospital stay was 7 days in the dexamethasone group and 3 days in the control group (P < 0.001). No significant differences were observed in the other outcomes. This study showed that corticosteroid administration had no clinical benefit in patients with COVID-19-induced mild to moderate ARDS.

Keywords: COVID-19; Corticosteroids; Dexamethasone; SARS-Cov-2.